Amylyx Pharmaceuticals, Inc. share price logo

Amylyx Pharmaceuticals, Inc. Share Price

NASDAQ: AMLX

Small Cap

$13.56

+0.09

(+0.67%)

as on

Amylyx Pharmaceuticals, Inc. Stock Performance

as on March 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $13.32
    $13.83
    downward going graph

    1.77%

    Downside

    1.99%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.11
    $17.49
    downward going graph

    77.06%

    Downside

    28.98%

    Upside

    downward going graph

Amylyx Pharmaceuticals, Inc. share price movements today

Previous Close
$13.47
Open
$13.54
Volume
1.1M
Day's Low - High
$13.32 - $13.83
52 Week Low - High
$3.11 - $17.49

Amylyx Pharmaceuticals, Inc. Historical Returns

1 Month Return
-10.68 %
3 Month Return
+ 9.89 %
1 Year Return
+ 270.22 %
3 Year Return
-55.59 %
5 Year Return
0 %

Amylyx Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators

Check Amylyx Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.5B

EPS (TTM)

-1.305

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.87

Industry PE ratio

-4.397180327868853

PEG Ratio

0

EBITDA

-152.8M

Revenue (TTM)

-665.0K

Profit Margin

0.00%

Return On Equity TTM

-61.59%

Amylyx Pharmaceuticals, Inc. Stock Valuation

Track how Amylyx Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.

Amylyx Pharmaceuticals, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-21.78x)

June 30, 2023

Industry (-4.40x)

March 28, 2026

Today (-0.87x)

March 28, 2026

Highest (23.35x)

March 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -0.87x

Amylyx Pharmaceuticals, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Amylyx Pharmaceuticals, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Amylyx Pharmaceuticals, Inc. image
Amylyx Pharmaceuticals, Inc.
BUY$1.5BNA-0.870.00%
United Therapeutics Corporation image
United Therapeutics Corporation
BUY$22.9BNA18.7741.94%
Viatris Inc. image
Viatris Inc.
HOLD$15.4B-9.12%-21.95-24.58%
Haleon Plc Spon Ads image
Haleon Plc Spon Ads
BUY$43.5BNA19.515.11%
Zoetis Inc. image
Zoetis Inc.
BUY$51.4B-27.41%19.3728.24%

Stock Returns calculator for Amylyx Pharmaceuticals, Inc. Stock including INR - Dollar returns

The Amylyx Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Amylyx Pharmaceuticals, Inc. investment value today

Current value as on today

₹4,10,246

Returns

₹3,10,246

(+310.25%)

Returns from Amylyx Pharmaceuticals, Inc. Stock

₹2,70,492 (+270.49%)

Dollar Impact

₹39,754 (+39.75%)

Analyst Recommendation on Amylyx Pharmaceuticals, Inc. Stock

Based on 13 analysts

BUY

53.85%

Buy

46.15%

Hold

0.00%

Sell

Based on 13 analysts, 53.85% of analysts recommend a 'BUY' rating for Amylyx Pharmaceuticals, Inc.. Average target price of $22.8

Amylyx Pharmaceuticals, Inc. Share Price Target

Get share price movements and forecasts by analysts on Amylyx Pharmaceuticals, Inc..

What analysts predicted

40.53%UPSIDE

Target Price

$22.8

Current Price

$13.56

Analyzed by

13 Analysts

Target

$22.80

Amylyx Pharmaceuticals, Inc. target price $22.8, a slight upside of 40.53% compared to current price of $13.56. According to 13 analysts rating.

Amylyx Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest

Search interest for Amylyx Pharmaceuticals, Inc. Stock has decreased by -49% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-49% versus previous 30 day period

Amylyx Pharmaceuticals, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
102
108
88
-1
0
0
-
-
-
-
Gross Profit
97
99
-27
-8
0
0
-
0
-19
0
Operating Income
18
1
-122
-53
-75
-40
-37
-42
-36
-36
EBITDA
19
2
-121
-53
-75
-40
-37
-41
-34
-30
Interest Expense
-
3
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
22
6
-118
-72
-72
-38
-35
-41
-34
-32
Income Tax Expense
1
1
0
-
-72
0
-
-
-
0
Net Income
20
4
-118
-72
-72
-37
-35
-41
-34
-32
Net Profit Margin
20.35%
4.36%
-134.01%
7106.55%
-17476.92%
5646.02%
0.00%
0.00%
0.00%
0.00%

Amylyx Pharmaceuticals, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
0
0
22
380
87
-
Gross Profit
-10
-23
0
19
355
45
0
Operating Income
-13
-39
-82
-201
38
-314
-153
EBITDA
1
-39
-82
-200
39
-290
-144
Interest Expense
1
2
0
4
-
-
-
Depreciation
-
0
0
0
1
0
0
Income Before Tax
-13
-42
-87
-197
54
-302
-144
Income Tax Expense
1
2
0
0
5
0
0
Net Income
-14
-42
-87
-198
49
-301
-144
Net Profit Margin
-1038.99%
-6504.62%
-30834.74%
-892.38%
12.94%
-345.36%
0.00%

Amylyx Pharmaceuticals, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
4
-118
-72
-72
-37
-35
-41
-34
-32
Operating Cash Flow
13
0
-66
-41
-59
-39
-25
-30
-27
Investing Cash Flow
20
0
-28
38
64
-43
22
5
29
Financing Cash Flow
0
0
0
0
0
65
0
191
0
Change in Cash
34
0
-95
-2
5
-17
-1
167
1

Amylyx Pharmaceuticals, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-42
-87
-198
49
-301
-144
Operating Cash Flow
-36
-74
-179
11
-167
-123
Investing Cash Flow
0
-46
-238
92
75
14
Financing Cash Flow
46
158
431
3
0
257
Change in Cash
9
37
12
107
-92
148

Global Institutional Holdings in Amylyx Pharmaceuticals, Inc.

Funds
Holdings
Vanguard Group Inc
5.25%
Great Point Partners LLC
1.54%
683 Capital Management LLC
1.49%
683 Capital Management LLC
1.6%
Almitas Capital LLC
1.92%
See all

Insights on Amylyx Pharmaceuticals, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, AMLX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, AMLX stock has moved up by 270.2%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -41.44M → -32.99M (in $), with an average increase of 12.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation has given 138.7% return, outperforming this stock by 189.8%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 416.0K → -665.0K (in $), with an average decrease of 259.9% per quarter

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.
OrganisationAmylyx Pharmaceuticals, Inc.
Headquarters55 Cambridge Parkway, Cambridge, MA, United States, 02142
IndustryServices
CEOMr. Joshua B. Cohen
E-voting on sharesClick here to vote

Key Management of Amylyx Pharmaceuticals, Inc.

Name

Title

Mr. James M. Frates M.B.A.

Chief Financial Officer

Ms. Gina M. Mazzariello J.D.

Chief Legal Officer & General Counsel

Ms. Tammy Sarnelli

Global Head of Regulatory Affairs

Dr. Machelle Manuel Ph.D.

VP & Head of Global Medical Affairs

Dr. Jamie Timmons

Head of Global Medical Strategy & Communications

Mr. Joshua B. Cohen

Co-Founder, Co-CEO & Director

Mr. Justin B. Klee

Co-Founder, Co-CEO & Director

Mr. Tom Holmes

Chief Technical Operations Officer

Ms. Lindsey Allen

Head of Investor Relations & Communications

Ms. Linda A. Arsenault

Chief Human Resources Officer

FAQs

What is Amylyx Pharmaceuticals, Inc. share price today?

Amylyx Pharmaceuticals, Inc. share price today is $13.56 as on at the close of the market. Amylyx Pharmaceuticals, Inc. share today touched a day high of $13.83 and a low of $13.32.

What is the 52 week high and 52 week low for Amylyx Pharmaceuticals, Inc. share?

Amylyx Pharmaceuticals, Inc. share touched a 52 week high of $17.49 on and a 52 week low of $3.11 on . Amylyx Pharmaceuticals, Inc. stock price today i.e. is closed at $13.56,which is 22.47% down from its 52 week high and 336.01% up from its 52 week low.

What is Amylyx Pharmaceuticals, Inc.'s market capitalisation today?

Amylyx Pharmaceuticals, Inc. market capitalisation is $0.00T as on .

How to invest in Amylyx Pharmaceuticals, Inc. Stock (AMLX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Amylyx Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Amylyx Pharmaceuticals, Inc. Shares that will get you 0.1106 shares as per Amylyx Pharmaceuticals, Inc. share price of $13.56 per share as on March 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Amylyx Pharmaceuticals, Inc. Stock (AMLX) from India?

Indian investors can start investing in Amylyx Pharmaceuticals, Inc. (AMLX) shares with as little as ₹94.63 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.30 in Amylyx Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Amylyx Pharmaceuticals, Inc. share’s latest price of $13.56 as on March 28, 2026 at 1:29 am IST, you will get 0.7375 shares of Amylyx Pharmaceuticals, Inc.. Learn more about fractional shares .